nodes	percent_of_prediction	percent_of_DWPC	metapath
Oxaprozin—osteoarthritis—Prednisone—chronic obstructive pulmonary disease	0.551	1	CpDpCtD
Oxaprozin—PTGS1—Montelukast—chronic obstructive pulmonary disease	0.116	0.406	CbGbCtD
Oxaprozin—CYP2C9—Arformoterol—chronic obstructive pulmonary disease	0.0618	0.215	CbGbCtD
Oxaprozin—CYP2C9—Formoterol—chronic obstructive pulmonary disease	0.0618	0.215	CbGbCtD
Oxaprozin—CYP2C9—Montelukast—chronic obstructive pulmonary disease	0.0468	0.163	CbGbCtD
Oxaprozin—PTGS1—Prostaglandin Synthesis and Regulation—SCGB1A1—chronic obstructive pulmonary disease	0.00155	0.0675	CbGpPWpGaD
Oxaprozin—PTGS2—Prostaglandin Synthesis and Regulation—SCGB1A1—chronic obstructive pulmonary disease	0.00123	0.0536	CbGpPWpGaD
Oxaprozin—CYP2C9—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1A2—chronic obstructive pulmonary disease	0.000738	0.0322	CbGpPWpGaD
Oxaprozin—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—chronic obstructive pulmonary disease	0.000685	0.0298	CbGpPWpGaD
Oxaprozin—CYP2C9—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1A2—chronic obstructive pulmonary disease	0.000672	0.0293	CbGpPWpGaD
Oxaprozin—PTGS1—Overview of nanoparticle effects—HMOX1—chronic obstructive pulmonary disease	0.000578	0.0252	CbGpPWpGaD
Oxaprozin—PTGS2—C-MYB transcription factor network—ELANE—chronic obstructive pulmonary disease	0.00054	0.0235	CbGpPWpGaD
Oxaprozin—CYP2C9—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1A1—chronic obstructive pulmonary disease	0.000537	0.0234	CbGpPWpGaD
Oxaprozin—CYP2C9—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1A1—chronic obstructive pulmonary disease	0.000488	0.0213	CbGpPWpGaD
Oxaprozin—PTGS2—Overview of nanoparticle effects—HMOX1—chronic obstructive pulmonary disease	0.000459	0.02	CbGpPWpGaD
Oxaprozin—PTGS1—Overview of nanoparticle effects—CRP—chronic obstructive pulmonary disease	0.000453	0.0197	CbGpPWpGaD
Oxaprozin—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—MMP1—chronic obstructive pulmonary disease	0.000417	0.0182	CbGpPWpGaD
Oxaprozin—PTGS1—Prostaglandin Synthesis and Regulation—EDN1—chronic obstructive pulmonary disease	0.000378	0.0165	CbGpPWpGaD
Oxaprozin—PTGS1—Selenium Micronutrient Network—SOD3—chronic obstructive pulmonary disease	0.000377	0.0164	CbGpPWpGaD
Oxaprozin—PTGS2—Overview of nanoparticle effects—CRP—chronic obstructive pulmonary disease	0.00036	0.0157	CbGpPWpGaD
Oxaprozin—CYP2C9—Xenobiotics—CYP1A2—chronic obstructive pulmonary disease	0.000355	0.0154	CbGpPWpGaD
Oxaprozin—CYP2C9—Tamoxifen metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000341	0.0149	CbGpPWpGaD
Oxaprozin—Warfarin—CYP1A1—chronic obstructive pulmonary disease	0.000341	0.132	CrCbGaD
Oxaprozin—Warfarin—CYP1A2—chronic obstructive pulmonary disease	0.000329	0.128	CrCbGaD
Oxaprozin—PTGS2—Aryl Hydrocarbon Receptor—GCLC—chronic obstructive pulmonary disease	0.000327	0.0142	CbGpPWpGaD
Oxaprozin—PTGS1—Arachidonic acid metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000324	0.0141	CbGpPWpGaD
Oxaprozin—Propafenone—CYP1A2—chronic obstructive pulmonary disease	0.000321	0.125	CrCbGaD
Oxaprozin—PTGS2—Prostaglandin Synthesis and Regulation—EDN1—chronic obstructive pulmonary disease	0.0003	0.0131	CbGpPWpGaD
Oxaprozin—PTGS2—Selenium Micronutrient Network—SOD3—chronic obstructive pulmonary disease	0.000299	0.013	CbGpPWpGaD
Oxaprozin—Anaphylactoid reaction—Prednisolone—chronic obstructive pulmonary disease	0.000299	0.00218	CcSEcCtD
Oxaprozin—Ill-defined disorder—Formoterol—chronic obstructive pulmonary disease	0.000298	0.00218	CcSEcCtD
Oxaprozin—Ill-defined disorder—Arformoterol—chronic obstructive pulmonary disease	0.000298	0.00218	CcSEcCtD
Oxaprozin—Tension—Salbutamol—chronic obstructive pulmonary disease	0.000298	0.00218	CcSEcCtD
Oxaprozin—Dysgeusia—Salbutamol—chronic obstructive pulmonary disease	0.000297	0.00217	CcSEcCtD
Oxaprozin—Vasculitis—Prednisone—chronic obstructive pulmonary disease	0.000297	0.00217	CcSEcCtD
Oxaprozin—Tremor—Montelukast—chronic obstructive pulmonary disease	0.000295	0.00216	CcSEcCtD
Oxaprozin—Nervousness—Salbutamol—chronic obstructive pulmonary disease	0.000295	0.00215	CcSEcCtD
Oxaprozin—PTGS1—Overview of nanoparticle effects—CXCL8—chronic obstructive pulmonary disease	0.000295	0.0128	CbGpPWpGaD
Oxaprozin—Insomnia—Tiotropium—chronic obstructive pulmonary disease	0.000294	0.00215	CcSEcCtD
Oxaprozin—Angioedema—Formoterol—chronic obstructive pulmonary disease	0.000294	0.00215	CcSEcCtD
Oxaprozin—Angioedema—Arformoterol—chronic obstructive pulmonary disease	0.000294	0.00215	CcSEcCtD
Oxaprozin—PTGS2—Spinal Cord Injury—MMP12—chronic obstructive pulmonary disease	0.000293	0.0128	CbGpPWpGaD
Oxaprozin—Paraesthesia—Tiotropium—chronic obstructive pulmonary disease	0.000292	0.00213	CcSEcCtD
Oxaprozin—Malaise—Arformoterol—chronic obstructive pulmonary disease	0.00029	0.00212	CcSEcCtD
Oxaprozin—Malaise—Formoterol—chronic obstructive pulmonary disease	0.00029	0.00212	CcSEcCtD
Oxaprozin—Angioedema—Montelukast—chronic obstructive pulmonary disease	0.000288	0.0021	CcSEcCtD
Oxaprozin—Dyspepsia—Tiotropium—chronic obstructive pulmonary disease	0.000286	0.00209	CcSEcCtD
Oxaprozin—Tremor—Salbutamol—chronic obstructive pulmonary disease	0.000284	0.00208	CcSEcCtD
Oxaprozin—Palpitations—Arformoterol—chronic obstructive pulmonary disease	0.000284	0.00208	CcSEcCtD
Oxaprozin—Palpitations—Formoterol—chronic obstructive pulmonary disease	0.000284	0.00208	CcSEcCtD
Oxaprozin—Gastrointestinal pain—Aminophylline—chronic obstructive pulmonary disease	0.000282	0.00206	CcSEcCtD
Oxaprozin—Ill-defined disorder—Salbutamol—chronic obstructive pulmonary disease	0.000282	0.00206	CcSEcCtD
Oxaprozin—Palpitations—Montelukast—chronic obstructive pulmonary disease	0.000278	0.00203	CcSEcCtD
Oxaprozin—Constipation—Tiotropium—chronic obstructive pulmonary disease	0.000278	0.00203	CcSEcCtD
Oxaprozin—Hypertension—Arformoterol—chronic obstructive pulmonary disease	0.000278	0.00203	CcSEcCtD
Oxaprozin—Hypertension—Formoterol—chronic obstructive pulmonary disease	0.000278	0.00203	CcSEcCtD
Oxaprozin—Angioedema—Salbutamol—chronic obstructive pulmonary disease	0.000277	0.00203	CcSEcCtD
Oxaprozin—PTGS2—Aryl Hydrocarbon Receptor—CYP1A2—chronic obstructive pulmonary disease	0.000275	0.012	CbGpPWpGaD
Oxaprozin—Urticaria—Aminophylline—chronic obstructive pulmonary disease	0.000274	0.002	CcSEcCtD
Oxaprozin—Malaise—Salbutamol—chronic obstructive pulmonary disease	0.000274	0.002	CcSEcCtD
Oxaprozin—Convulsion—Montelukast—chronic obstructive pulmonary disease	0.000273	0.00199	CcSEcCtD
Oxaprozin—Anxiety—Formoterol—chronic obstructive pulmonary disease	0.000273	0.00199	CcSEcCtD
Oxaprozin—Anxiety—Arformoterol—chronic obstructive pulmonary disease	0.000273	0.00199	CcSEcCtD
Oxaprozin—Vertigo—Salbutamol—chronic obstructive pulmonary disease	0.000273	0.00199	CcSEcCtD
Oxaprozin—Abdominal pain—Aminophylline—chronic obstructive pulmonary disease	0.000273	0.00199	CcSEcCtD
Oxaprozin—Body temperature increased—Aminophylline—chronic obstructive pulmonary disease	0.000273	0.00199	CcSEcCtD
Oxaprozin—Syncope—Salbutamol—chronic obstructive pulmonary disease	0.000272	0.00199	CcSEcCtD
Oxaprozin—Discomfort—Formoterol—chronic obstructive pulmonary disease	0.00027	0.00198	CcSEcCtD
Oxaprozin—Discomfort—Arformoterol—chronic obstructive pulmonary disease	0.00027	0.00198	CcSEcCtD
Oxaprozin—Modafinil—CYP1A2—chronic obstructive pulmonary disease	0.000269	0.104	CrCbGaD
Oxaprozin—Palpitations—Salbutamol—chronic obstructive pulmonary disease	0.000268	0.00196	CcSEcCtD
Oxaprozin—Dry mouth—Arformoterol—chronic obstructive pulmonary disease	0.000268	0.00196	CcSEcCtD
Oxaprozin—Dry mouth—Formoterol—chronic obstructive pulmonary disease	0.000268	0.00196	CcSEcCtD
Oxaprozin—Anxiety—Montelukast—chronic obstructive pulmonary disease	0.000267	0.00195	CcSEcCtD
Oxaprozin—Loss of consciousness—Salbutamol—chronic obstructive pulmonary disease	0.000267	0.00195	CcSEcCtD
Oxaprozin—Gastrointestinal pain—Tiotropium—chronic obstructive pulmonary disease	0.000266	0.00194	CcSEcCtD
Oxaprozin—Oesophagitis—Prednisone—chronic obstructive pulmonary disease	0.000264	0.00193	CcSEcCtD
Oxaprozin—Anaphylactic shock—Arformoterol—chronic obstructive pulmonary disease	0.000262	0.00192	CcSEcCtD
Oxaprozin—Oedema—Arformoterol—chronic obstructive pulmonary disease	0.000262	0.00192	CcSEcCtD
Oxaprozin—Oedema—Formoterol—chronic obstructive pulmonary disease	0.000262	0.00192	CcSEcCtD
Oxaprozin—Anaphylactic shock—Formoterol—chronic obstructive pulmonary disease	0.000262	0.00192	CcSEcCtD
Oxaprozin—Hypertension—Salbutamol—chronic obstructive pulmonary disease	0.000262	0.00191	CcSEcCtD
Oxaprozin—Ecchymosis—Prednisone—chronic obstructive pulmonary disease	0.000262	0.00191	CcSEcCtD
Oxaprozin—Infection—Formoterol—chronic obstructive pulmonary disease	0.000261	0.0019	CcSEcCtD
Oxaprozin—Infection—Arformoterol—chronic obstructive pulmonary disease	0.000261	0.0019	CcSEcCtD
Oxaprozin—Urticaria—Tiotropium—chronic obstructive pulmonary disease	0.000258	0.00189	CcSEcCtD
Oxaprozin—CYP2C9—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	0.000258	0.0112	CbGpPWpGaD
Oxaprozin—Anxiety—Salbutamol—chronic obstructive pulmonary disease	0.000258	0.00188	CcSEcCtD
Oxaprozin—PTGS2—Arachidonic acid metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000257	0.0112	CbGpPWpGaD
Oxaprozin—Abdominal pain—Tiotropium—chronic obstructive pulmonary disease	0.000257	0.00188	CcSEcCtD
Oxaprozin—Oedema—Montelukast—chronic obstructive pulmonary disease	0.000257	0.00188	CcSEcCtD
Oxaprozin—Anaphylactic shock—Montelukast—chronic obstructive pulmonary disease	0.000257	0.00188	CcSEcCtD
Oxaprozin—Tachycardia—Arformoterol—chronic obstructive pulmonary disease	0.000256	0.00187	CcSEcCtD
Oxaprozin—Tachycardia—Formoterol—chronic obstructive pulmonary disease	0.000256	0.00187	CcSEcCtD
Oxaprozin—Discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000255	0.00187	CcSEcCtD
Oxaprozin—Infection—Montelukast—chronic obstructive pulmonary disease	0.000255	0.00187	CcSEcCtD
Oxaprozin—Dry mouth—Salbutamol—chronic obstructive pulmonary disease	0.000253	0.00185	CcSEcCtD
Oxaprozin—PTGS1—Selenium Micronutrient Network—MPO—chronic obstructive pulmonary disease	0.000253	0.011	CbGpPWpGaD
Oxaprozin—Thrombocytopenia—Montelukast—chronic obstructive pulmonary disease	0.000252	0.00184	CcSEcCtD
Oxaprozin—Sepsis—Prednisone—chronic obstructive pulmonary disease	0.000251	0.00183	CcSEcCtD
Oxaprozin—CYP2C9—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000248	0.0108	CbGpPWpGaD
Oxaprozin—Oedema—Salbutamol—chronic obstructive pulmonary disease	0.000248	0.00181	CcSEcCtD
Oxaprozin—Anaphylactic shock—Salbutamol—chronic obstructive pulmonary disease	0.000248	0.00181	CcSEcCtD
Oxaprozin—Infection—Salbutamol—chronic obstructive pulmonary disease	0.000246	0.0018	CcSEcCtD
Oxaprozin—Carbamazepine—CYP1A2—chronic obstructive pulmonary disease	0.000246	0.0953	CrCbGaD
Oxaprozin—Hypotension—Arformoterol—chronic obstructive pulmonary disease	0.000245	0.00179	CcSEcCtD
Oxaprozin—Hypotension—Formoterol—chronic obstructive pulmonary disease	0.000245	0.00179	CcSEcCtD
Oxaprozin—Pancreatitis—Prednisolone—chronic obstructive pulmonary disease	0.000245	0.00179	CcSEcCtD
Oxaprozin—Pruritus—Aminophylline—chronic obstructive pulmonary disease	0.000244	0.00178	CcSEcCtD
Oxaprozin—Shock—Salbutamol—chronic obstructive pulmonary disease	0.000244	0.00178	CcSEcCtD
Oxaprozin—Sweating increased—Prednisolone—chronic obstructive pulmonary disease	0.000243	0.00178	CcSEcCtD
Oxaprozin—Tachycardia—Salbutamol—chronic obstructive pulmonary disease	0.000242	0.00177	CcSEcCtD
Oxaprozin—Hyperhidrosis—Salbutamol—chronic obstructive pulmonary disease	0.00024	0.00175	CcSEcCtD
Oxaprozin—Insomnia—Arformoterol—chronic obstructive pulmonary disease	0.000237	0.00173	CcSEcCtD
Oxaprozin—Insomnia—Formoterol—chronic obstructive pulmonary disease	0.000237	0.00173	CcSEcCtD
Oxaprozin—Anorexia—Salbutamol—chronic obstructive pulmonary disease	0.000236	0.00173	CcSEcCtD
Oxaprozin—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.000236	0.00172	CcSEcCtD
Oxaprozin—PTGS1—Arachidonic acid metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000236	0.0103	CbGpPWpGaD
Oxaprozin—Vascular purpura—Prednisone—chronic obstructive pulmonary disease	0.000235	0.00172	CcSEcCtD
Oxaprozin—PTGS2—Overview of nanoparticle effects—CXCL8—chronic obstructive pulmonary disease	0.000234	0.0102	CbGpPWpGaD
Oxaprozin—Dyspnoea—Formoterol—chronic obstructive pulmonary disease	0.000234	0.00171	CcSEcCtD
Oxaprozin—Dyspnoea—Arformoterol—chronic obstructive pulmonary disease	0.000234	0.00171	CcSEcCtD
Oxaprozin—Somnolence—Formoterol—chronic obstructive pulmonary disease	0.000233	0.0017	CcSEcCtD
Oxaprozin—Somnolence—Arformoterol—chronic obstructive pulmonary disease	0.000233	0.0017	CcSEcCtD
Oxaprozin—Insomnia—Montelukast—chronic obstructive pulmonary disease	0.000232	0.0017	CcSEcCtD
Oxaprozin—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP1A2—chronic obstructive pulmonary disease	0.000232	0.0101	CbGpPWpGaD
Oxaprozin—Cardiac failure congestive—Prednisone—chronic obstructive pulmonary disease	0.000232	0.00169	CcSEcCtD
Oxaprozin—Hypotension—Salbutamol—chronic obstructive pulmonary disease	0.000232	0.00169	CcSEcCtD
Oxaprozin—Dyspepsia—Arformoterol—chronic obstructive pulmonary disease	0.000231	0.00169	CcSEcCtD
Oxaprozin—Dyspepsia—Formoterol—chronic obstructive pulmonary disease	0.000231	0.00169	CcSEcCtD
Oxaprozin—Paraesthesia—Montelukast—chronic obstructive pulmonary disease	0.000231	0.00169	CcSEcCtD
Oxaprozin—Pruritus—Tiotropium—chronic obstructive pulmonary disease	0.00023	0.00168	CcSEcCtD
Oxaprozin—Somnolence—Montelukast—chronic obstructive pulmonary disease	0.000228	0.00167	CcSEcCtD
Oxaprozin—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.000228	0.00167	CcSEcCtD
Oxaprozin—PTGS1—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	0.000227	0.00989	CbGpPWpGaD
Oxaprozin—Dyspepsia—Montelukast—chronic obstructive pulmonary disease	0.000226	0.00165	CcSEcCtD
Oxaprozin—Constipation—Formoterol—chronic obstructive pulmonary disease	0.000224	0.00164	CcSEcCtD
Oxaprozin—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.000224	0.00164	CcSEcCtD
Oxaprozin—Insomnia—Salbutamol—chronic obstructive pulmonary disease	0.000224	0.00164	CcSEcCtD
Oxaprozin—Paraesthesia—Salbutamol—chronic obstructive pulmonary disease	0.000222	0.00163	CcSEcCtD
Oxaprozin—Dyspnoea—Salbutamol—chronic obstructive pulmonary disease	0.000221	0.00161	CcSEcCtD
Oxaprozin—Somnolence—Salbutamol—chronic obstructive pulmonary disease	0.00022	0.00161	CcSEcCtD
Oxaprozin—Acute coronary syndrome—Prednisolone—chronic obstructive pulmonary disease	0.00022	0.0016	CcSEcCtD
Oxaprozin—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.000219	0.0016	CcSEcCtD
Oxaprozin—Myocardial infarction—Prednisolone—chronic obstructive pulmonary disease	0.000218	0.0016	CcSEcCtD
Oxaprozin—Dyspepsia—Salbutamol—chronic obstructive pulmonary disease	0.000218	0.00159	CcSEcCtD
Oxaprozin—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—chronic obstructive pulmonary disease	0.000218	0.00949	CbGpPWpGaD
Oxaprozin—Purpura—Prednisone—chronic obstructive pulmonary disease	0.000218	0.00159	CcSEcCtD
Oxaprozin—Rash—Aminophylline—chronic obstructive pulmonary disease	0.000217	0.00159	CcSEcCtD
Oxaprozin—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.000217	0.00159	CcSEcCtD
Oxaprozin—Conjunctivitis—Prednisolone—chronic obstructive pulmonary disease	0.000217	0.00158	CcSEcCtD
Oxaprozin—Feeling abnormal—Formoterol—chronic obstructive pulmonary disease	0.000216	0.00158	CcSEcCtD
Oxaprozin—Feeling abnormal—Arformoterol—chronic obstructive pulmonary disease	0.000216	0.00158	CcSEcCtD
Oxaprozin—Headache—Aminophylline—chronic obstructive pulmonary disease	0.000216	0.00158	CcSEcCtD
Oxaprozin—Decreased appetite—Salbutamol—chronic obstructive pulmonary disease	0.000215	0.00157	CcSEcCtD
Oxaprozin—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.000215	0.00157	CcSEcCtD
Oxaprozin—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	0.000215	0.00157	CcSEcCtD
Oxaprozin—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	0.000215	0.00157	CcSEcCtD
Oxaprozin—Lethargy—Prednisone—chronic obstructive pulmonary disease	0.000214	0.00157	CcSEcCtD
Oxaprozin—Phenprocoumon—ALB—chronic obstructive pulmonary disease	0.000214	0.083	CrCbGaD
Oxaprozin—Constipation—Salbutamol—chronic obstructive pulmonary disease	0.000212	0.00155	CcSEcCtD
Oxaprozin—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	0.00021	0.00154	CcSEcCtD
Oxaprozin—Gastrointestinal haemorrhage—Prednisone—chronic obstructive pulmonary disease	0.00021	0.00153	CcSEcCtD
Oxaprozin—Urticaria—Formoterol—chronic obstructive pulmonary disease	0.000208	0.00152	CcSEcCtD
Oxaprozin—Urticaria—Arformoterol—chronic obstructive pulmonary disease	0.000208	0.00152	CcSEcCtD
Oxaprozin—PTGS2—C-MYB transcription factor network—MPO—chronic obstructive pulmonary disease	0.000208	0.00907	CbGpPWpGaD
Oxaprozin—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	0.000207	0.00152	CcSEcCtD
Oxaprozin—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	0.000207	0.00152	CcSEcCtD
Oxaprozin—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	0.000207	0.00152	CcSEcCtD
Oxaprozin—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	0.000207	0.00152	CcSEcCtD
Oxaprozin—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.000207	0.00151	CcSEcCtD
Oxaprozin—PTGS1—Overview of nanoparticle effects—TNF—chronic obstructive pulmonary disease	0.000205	0.00893	CbGpPWpGaD
Oxaprozin—Rash—Tiotropium—chronic obstructive pulmonary disease	0.000205	0.0015	CcSEcCtD
Oxaprozin—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.000205	0.0015	CcSEcCtD
Oxaprozin—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.000205	0.0015	CcSEcCtD
Oxaprozin—Urticaria—Montelukast—chronic obstructive pulmonary disease	0.000204	0.00149	CcSEcCtD
Oxaprozin—Feeling abnormal—Salbutamol—chronic obstructive pulmonary disease	0.000204	0.00149	CcSEcCtD
Oxaprozin—Headache—Tiotropium—chronic obstructive pulmonary disease	0.000204	0.00149	CcSEcCtD
Oxaprozin—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	0.000203	0.00148	CcSEcCtD
Oxaprozin—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	0.000203	0.00148	CcSEcCtD
Oxaprozin—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	0.000203	0.00148	CcSEcCtD
Oxaprozin—PTGS2—Signaling mediated by p38-alpha and p38-beta—NOS2—chronic obstructive pulmonary disease	0.000201	0.00876	CbGpPWpGaD
Oxaprozin—Haemoglobin—Prednisolone—chronic obstructive pulmonary disease	0.000201	0.00147	CcSEcCtD
Oxaprozin—PTGS2—Selenium Micronutrient Network—MPO—chronic obstructive pulmonary disease	0.000201	0.00874	CbGpPWpGaD
Oxaprozin—Haemorrhage—Prednisolone—chronic obstructive pulmonary disease	0.0002	0.00146	CcSEcCtD
Oxaprozin—PTGS2—Aryl Hydrocarbon Receptor—CYP1A1—chronic obstructive pulmonary disease	0.0002	0.0087	CbGpPWpGaD
Oxaprozin—PTGS2—Integrated Pancreatic Cancer Pathway—RAPGEF3—chronic obstructive pulmonary disease	0.000199	0.00869	CbGpPWpGaD
Oxaprozin—Urticaria—Salbutamol—chronic obstructive pulmonary disease	0.000197	0.00144	CcSEcCtD
Oxaprozin—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	0.000196	0.00143	CcSEcCtD
Oxaprozin—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	0.000196	0.00143	CcSEcCtD
Oxaprozin—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.000193	0.00141	CcSEcCtD
Oxaprozin—PTGS2—S1P1 pathway—VEGFA—chronic obstructive pulmonary disease	0.00019	0.00827	CbGpPWpGaD
Oxaprozin—Warfarin—ALB—chronic obstructive pulmonary disease	0.00019	0.0737	CrCbGaD
Oxaprozin—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.000188	0.00138	CcSEcCtD
Oxaprozin—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.000188	0.00138	CcSEcCtD
Oxaprozin—Diphenhydramine—CYP1A2—chronic obstructive pulmonary disease	0.000187	0.0726	CrCbGaD
Oxaprozin—PTGS2—Arachidonic acid metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000187	0.00814	CbGpPWpGaD
Oxaprozin—Pruritus—Formoterol—chronic obstructive pulmonary disease	0.000186	0.00136	CcSEcCtD
Oxaprozin—Pruritus—Arformoterol—chronic obstructive pulmonary disease	0.000186	0.00136	CcSEcCtD
Oxaprozin—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.000184	0.00135	CcSEcCtD
Oxaprozin—Pruritus—Montelukast—chronic obstructive pulmonary disease	0.000182	0.00133	CcSEcCtD
Oxaprozin—Methadone—CYP1A2—chronic obstructive pulmonary disease	0.000181	0.0701	CrCbGaD
Oxaprozin—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.00018	0.00131	CcSEcCtD
Oxaprozin—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.00018	0.00131	CcSEcCtD
Oxaprozin—Arrhythmia—Prednisolone—chronic obstructive pulmonary disease	0.000179	0.00131	CcSEcCtD
Oxaprozin—Pancreatitis—Prednisone—chronic obstructive pulmonary disease	0.000178	0.0013	CcSEcCtD
Oxaprozin—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.000178	0.0013	CcSEcCtD
Oxaprozin—Sweating increased—Prednisone—chronic obstructive pulmonary disease	0.000177	0.00129	CcSEcCtD
Oxaprozin—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.000176	0.00128	CcSEcCtD
Oxaprozin—Pruritus—Salbutamol—chronic obstructive pulmonary disease	0.000175	0.00128	CcSEcCtD
Oxaprozin—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.000174	0.00127	CcSEcCtD
Oxaprozin—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.000174	0.00127	CcSEcCtD
Oxaprozin—CYP2C9—Arachidonic acid metabolism—CYP1A2—chronic obstructive pulmonary disease	0.00017	0.00742	CbGpPWpGaD
Oxaprozin—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.00017	0.00124	CcSEcCtD
Oxaprozin—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.00017	0.00124	CcSEcCtD
Oxaprozin—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.000167	0.00122	CcSEcCtD
Oxaprozin—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.000167	0.00122	CcSEcCtD
Oxaprozin—PTGS1—Overview of nanoparticle effects—IL6—chronic obstructive pulmonary disease	0.000166	0.00721	CbGpPWpGaD
Oxaprozin—Rash—Formoterol—chronic obstructive pulmonary disease	0.000165	0.00121	CcSEcCtD
Oxaprozin—Rash—Arformoterol—chronic obstructive pulmonary disease	0.000165	0.00121	CcSEcCtD
Oxaprozin—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.000165	0.00121	CcSEcCtD
Oxaprozin—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.000165	0.00121	CcSEcCtD
Oxaprozin—PTGS1—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	0.000165	0.00719	CbGpPWpGaD
Oxaprozin—Headache—Arformoterol—chronic obstructive pulmonary disease	0.000164	0.0012	CcSEcCtD
Oxaprozin—Headache—Formoterol—chronic obstructive pulmonary disease	0.000164	0.0012	CcSEcCtD
Oxaprozin—Vision blurred—Prednisolone—chronic obstructive pulmonary disease	0.000164	0.0012	CcSEcCtD
Oxaprozin—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.000164	0.0012	CcSEcCtD
Oxaprozin—Hyperglycaemia—Prednisone—chronic obstructive pulmonary disease	0.000164	0.0012	CcSEcCtD
Oxaprozin—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.000163	0.00119	CcSEcCtD
Oxaprozin—PTGS2—Overview of nanoparticle effects—TNF—chronic obstructive pulmonary disease	0.000163	0.00709	CbGpPWpGaD
Oxaprozin—Rash—Montelukast—chronic obstructive pulmonary disease	0.000162	0.00118	CcSEcCtD
Oxaprozin—Flurbiprofen—ALB—chronic obstructive pulmonary disease	0.000162	0.0628	CrCbGaD
Oxaprozin—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.000162	0.00118	CcSEcCtD
Oxaprozin—Ill-defined disorder—Prednisolone—chronic obstructive pulmonary disease	0.000162	0.00118	CcSEcCtD
Oxaprozin—Headache—Montelukast—chronic obstructive pulmonary disease	0.000161	0.00118	CcSEcCtD
Oxaprozin—Acute coronary syndrome—Prednisone—chronic obstructive pulmonary disease	0.00016	0.00117	CcSEcCtD
Oxaprozin—Angioedema—Prednisolone—chronic obstructive pulmonary disease	0.000159	0.00116	CcSEcCtD
Oxaprozin—Myocardial infarction—Prednisone—chronic obstructive pulmonary disease	0.000159	0.00116	CcSEcCtD
Oxaprozin—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.000158	0.00115	CcSEcCtD
Oxaprozin—Malaise—Prednisolone—chronic obstructive pulmonary disease	0.000157	0.00115	CcSEcCtD
Oxaprozin—Vertigo—Prednisolone—chronic obstructive pulmonary disease	0.000156	0.00114	CcSEcCtD
Oxaprozin—Rash—Salbutamol—chronic obstructive pulmonary disease	0.000156	0.00114	CcSEcCtD
Oxaprozin—Syncope—Prednisolone—chronic obstructive pulmonary disease	0.000156	0.00114	CcSEcCtD
Oxaprozin—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.000156	0.00114	CcSEcCtD
Oxaprozin—Nausea—Formoterol—chronic obstructive pulmonary disease	0.000156	0.00114	CcSEcCtD
Oxaprozin—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.000156	0.00114	CcSEcCtD
Oxaprozin—Headache—Salbutamol—chronic obstructive pulmonary disease	0.000155	0.00113	CcSEcCtD
Oxaprozin—Loss of consciousness—Prednisolone—chronic obstructive pulmonary disease	0.000153	0.00112	CcSEcCtD
Oxaprozin—Nausea—Montelukast—chronic obstructive pulmonary disease	0.000153	0.00112	CcSEcCtD
Oxaprozin—Convulsion—Prednisolone—chronic obstructive pulmonary disease	0.000151	0.0011	CcSEcCtD
Oxaprozin—CYP2C9—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	0.000151	0.00656	CbGpPWpGaD
Oxaprozin—Hypertension—Prednisolone—chronic obstructive pulmonary disease	0.00015	0.0011	CcSEcCtD
Oxaprozin—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	0.000147	0.00641	CbGpPWpGaD
Oxaprozin—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.000147	0.00108	CcSEcCtD
Oxaprozin—Discomfort—Prednisolone—chronic obstructive pulmonary disease	0.000146	0.00107	CcSEcCtD
Oxaprozin—Haemoglobin—Prednisone—chronic obstructive pulmonary disease	0.000146	0.00107	CcSEcCtD
Oxaprozin—CYP2C9—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	0.000145	0.00633	CbGpPWpGaD
Oxaprozin—Haemorrhage—Prednisone—chronic obstructive pulmonary disease	0.000145	0.00106	CcSEcCtD
Oxaprozin—PTGS1—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	0.000145	0.00632	CbGpPWpGaD
Oxaprozin—Hallucination—Prednisone—chronic obstructive pulmonary disease	0.000145	0.00106	CcSEcCtD
Oxaprozin—PTGS1—Biological oxidations—GCLC—chronic obstructive pulmonary disease	0.000144	0.00625	CbGpPWpGaD
Oxaprozin—Oedema—Prednisolone—chronic obstructive pulmonary disease	0.000142	0.00104	CcSEcCtD
Oxaprozin—Anaphylactic shock—Prednisolone—chronic obstructive pulmonary disease	0.000142	0.00104	CcSEcCtD
Oxaprozin—Shock—Prednisolone—chronic obstructive pulmonary disease	0.00014	0.00102	CcSEcCtD
Oxaprozin—Tachycardia—Prednisolone—chronic obstructive pulmonary disease	0.000139	0.00101	CcSEcCtD
Oxaprozin—Phenytoin—ALB—chronic obstructive pulmonary disease	0.000138	0.0535	CrCbGaD
Oxaprozin—Hyperhidrosis—Prednisolone—chronic obstructive pulmonary disease	0.000137	0.001	CcSEcCtD
Oxaprozin—PTGS1—Selenium Micronutrient Network—CRP—chronic obstructive pulmonary disease	0.000133	0.00579	CbGpPWpGaD
Oxaprozin—PTGS2—Overview of nanoparticle effects—IL6—chronic obstructive pulmonary disease	0.000131	0.00572	CbGpPWpGaD
Oxaprozin—PTGS2—C-MYB transcription factor network—GSTM1—chronic obstructive pulmonary disease	0.00013	0.00567	CbGpPWpGaD
Oxaprozin—Arrhythmia—Prednisone—chronic obstructive pulmonary disease	0.00013	0.000949	CcSEcCtD
Oxaprozin—Insomnia—Prednisolone—chronic obstructive pulmonary disease	0.000129	0.000939	CcSEcCtD
Oxaprozin—Alopecia—Prednisone—chronic obstructive pulmonary disease	0.000128	0.000938	CcSEcCtD
Oxaprozin—Paraesthesia—Prednisolone—chronic obstructive pulmonary disease	0.000128	0.000932	CcSEcCtD
Oxaprozin—CYP2C9—Arachidonic acid metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000124	0.00539	CbGpPWpGaD
Oxaprozin—PTGS1—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	0.000121	0.00525	CbGpPWpGaD
Oxaprozin—CYP2C9—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	0.000119	0.0052	CbGpPWpGaD
Oxaprozin—Vision blurred—Prednisone—chronic obstructive pulmonary disease	0.000119	0.000871	CcSEcCtD
Oxaprozin—Ill-defined disorder—Prednisone—chronic obstructive pulmonary disease	0.000117	0.000858	CcSEcCtD
Oxaprozin—Feeling abnormal—Prednisolone—chronic obstructive pulmonary disease	0.000117	0.000855	CcSEcCtD
Oxaprozin—Anaemia—Prednisone—chronic obstructive pulmonary disease	0.000117	0.000854	CcSEcCtD
Oxaprozin—Angioedema—Prednisone—chronic obstructive pulmonary disease	0.000116	0.000845	CcSEcCtD
Oxaprozin—Malaise—Prednisone—chronic obstructive pulmonary disease	0.000114	0.000834	CcSEcCtD
Oxaprozin—Vertigo—Prednisone—chronic obstructive pulmonary disease	0.000114	0.00083	CcSEcCtD
Oxaprozin—Syncope—Prednisone—chronic obstructive pulmonary disease	0.000113	0.000829	CcSEcCtD
Oxaprozin—Urticaria—Prednisolone—chronic obstructive pulmonary disease	0.000113	0.000825	CcSEcCtD
Oxaprozin—Loss of consciousness—Prednisone—chronic obstructive pulmonary disease	0.000111	0.000812	CcSEcCtD
Oxaprozin—Convulsion—Prednisone—chronic obstructive pulmonary disease	0.00011	0.000801	CcSEcCtD
Oxaprozin—Hypertension—Prednisone—chronic obstructive pulmonary disease	0.000109	0.000798	CcSEcCtD
Oxaprozin—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CXCL8—chronic obstructive pulmonary disease	0.000108	0.0047	CbGpPWpGaD
Oxaprozin—Anxiety—Prednisone—chronic obstructive pulmonary disease	0.000107	0.000784	CcSEcCtD
Oxaprozin—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	0.000107	0.00466	CbGpPWpGaD
Oxaprozin—Discomfort—Prednisone—chronic obstructive pulmonary disease	0.000106	0.000777	CcSEcCtD
Oxaprozin—CYP2C9—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	0.000106	0.0046	CbGpPWpGaD
Oxaprozin—PTGS2—Selenium Micronutrient Network—CRP—chronic obstructive pulmonary disease	0.000106	0.00459	CbGpPWpGaD
Oxaprozin—Anaphylactic shock—Prednisone—chronic obstructive pulmonary disease	0.000103	0.000754	CcSEcCtD
Oxaprozin—Oedema—Prednisone—chronic obstructive pulmonary disease	0.000103	0.000754	CcSEcCtD
Oxaprozin—Infection—Prednisone—chronic obstructive pulmonary disease	0.000103	0.000749	CcSEcCtD
Oxaprozin—PTGS1—Selenium Micronutrient Network—SERPINE1—chronic obstructive pulmonary disease	0.000102	0.00444	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	0.000102	0.00444	CbGpPWpGaD
Oxaprozin—PTGS1—Selenium Micronutrient Network—ALB—chronic obstructive pulmonary disease	0.000102	0.00444	CbGpPWpGaD
Oxaprozin—Shock—Prednisone—chronic obstructive pulmonary disease	0.000102	0.000742	CcSEcCtD
Oxaprozin—Tachycardia—Prednisone—chronic obstructive pulmonary disease	0.000101	0.000736	CcSEcCtD
Oxaprozin—PTGS1—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	0.000101	0.00438	CbGpPWpGaD
Oxaprozin—Hyperhidrosis—Prednisone—chronic obstructive pulmonary disease	9.98e-05	0.000729	CcSEcCtD
Oxaprozin—Anorexia—Prednisone—chronic obstructive pulmonary disease	9.84e-05	0.000719	CcSEcCtD
Oxaprozin—Dizziness—Prednisolone—chronic obstructive pulmonary disease	9.4e-05	0.000686	CcSEcCtD
Oxaprozin—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—chronic obstructive pulmonary disease	9.37e-05	0.00408	CbGpPWpGaD
Oxaprozin—Insomnia—Prednisone—chronic obstructive pulmonary disease	9.34e-05	0.000682	CcSEcCtD
Oxaprozin—Paraesthesia—Prednisone—chronic obstructive pulmonary disease	9.27e-05	0.000677	CcSEcCtD
Oxaprozin—PTGS1—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	9.25e-05	0.00403	CbGpPWpGaD
Oxaprozin—Dyspepsia—Prednisone—chronic obstructive pulmonary disease	9.09e-05	0.000664	CcSEcCtD
Oxaprozin—Decreased appetite—Prednisone—chronic obstructive pulmonary disease	8.98e-05	0.000656	CcSEcCtD
Oxaprozin—Rash—Prednisolone—chronic obstructive pulmonary disease	8.96e-05	0.000655	CcSEcCtD
Oxaprozin—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	8.95e-05	0.000654	CcSEcCtD
Oxaprozin—Headache—Prednisolone—chronic obstructive pulmonary disease	8.9e-05	0.00065	CcSEcCtD
Oxaprozin—Constipation—Prednisone—chronic obstructive pulmonary disease	8.83e-05	0.000645	CcSEcCtD
Oxaprozin—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—chronic obstructive pulmonary disease	8.81e-05	0.00383	CbGpPWpGaD
Oxaprozin—PTGS1—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	8.77e-05	0.00382	CbGpPWpGaD
Oxaprozin—CYP2C9—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	8.68e-05	0.00378	CbGpPWpGaD
Oxaprozin—Feeling abnormal—Prednisone—chronic obstructive pulmonary disease	8.51e-05	0.000622	CcSEcCtD
Oxaprozin—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	8.44e-05	0.000617	CcSEcCtD
Oxaprozin—Nausea—Prednisolone—chronic obstructive pulmonary disease	8.44e-05	0.000617	CcSEcCtD
Oxaprozin—PTGS2—Aryl Hydrocarbon Receptor—EGFR—chronic obstructive pulmonary disease	8.43e-05	0.00367	CbGpPWpGaD
Oxaprozin—PTGS1—Selenium Micronutrient Network—IL1B—chronic obstructive pulmonary disease	8.29e-05	0.00361	CbGpPWpGaD
Oxaprozin—Urticaria—Prednisone—chronic obstructive pulmonary disease	8.2e-05	0.000599	CcSEcCtD
Oxaprozin—PTGS2—Spinal Cord Injury—LEP—chronic obstructive pulmonary disease	8.17e-05	0.00356	CbGpPWpGaD
Oxaprozin—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	8.16e-05	0.000596	CcSEcCtD
Oxaprozin—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	8.16e-05	0.000596	CcSEcCtD
Oxaprozin—PTGS2—Selenium Micronutrient Network—SERPINE1—chronic obstructive pulmonary disease	8.1e-05	0.00353	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	8.1e-05	0.00353	CbGpPWpGaD
Oxaprozin—PTGS2—Selenium Micronutrient Network—ALB—chronic obstructive pulmonary disease	8.09e-05	0.00352	CbGpPWpGaD
Oxaprozin—PTGS2—Aryl Hydrocarbon Receptor—TNF—chronic obstructive pulmonary disease	8.03e-05	0.00349	CbGpPWpGaD
Oxaprozin—PTGS2—Spinal Cord Injury—TLR4—chronic obstructive pulmonary disease	8e-05	0.00348	CbGpPWpGaD
Oxaprozin—CYP2C9—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	7.63e-05	0.00332	CbGpPWpGaD
Oxaprozin—PTGS2—Spinal Cord Injury—NOS2—chronic obstructive pulmonary disease	7.61e-05	0.00331	CbGpPWpGaD
Oxaprozin—CYP2C9—Biological oxidations—GCLC—chronic obstructive pulmonary disease	7.55e-05	0.00329	CbGpPWpGaD
Oxaprozin—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—chronic obstructive pulmonary disease	7.51e-05	0.00327	CbGpPWpGaD
Oxaprozin—Asthenia—Prednisone—chronic obstructive pulmonary disease	7.41e-05	0.000541	CcSEcCtD
Oxaprozin—Pruritus—Prednisone—chronic obstructive pulmonary disease	7.31e-05	0.000534	CcSEcCtD
Oxaprozin—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	7.06e-05	0.000516	CcSEcCtD
Oxaprozin—PTGS1—Metabolism—APIP—chronic obstructive pulmonary disease	7.05e-05	0.00307	CbGpPWpGaD
Oxaprozin—Dizziness—Prednisone—chronic obstructive pulmonary disease	6.83e-05	0.000499	CcSEcCtD
Oxaprozin—PTGS2—Selenium Micronutrient Network—IL1B—chronic obstructive pulmonary disease	6.58e-05	0.00287	CbGpPWpGaD
Oxaprozin—Vomiting—Prednisone—chronic obstructive pulmonary disease	6.57e-05	0.00048	CcSEcCtD
Oxaprozin—Rash—Prednisone—chronic obstructive pulmonary disease	6.51e-05	0.000476	CcSEcCtD
Oxaprozin—Dermatitis—Prednisone—chronic obstructive pulmonary disease	6.5e-05	0.000475	CcSEcCtD
Oxaprozin—Headache—Prednisone—chronic obstructive pulmonary disease	6.47e-05	0.000473	CcSEcCtD
Oxaprozin—CYP2C9—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	6.34e-05	0.00276	CbGpPWpGaD
Oxaprozin—CYP2C9—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	6.26e-05	0.00272	CbGpPWpGaD
Oxaprozin—Nausea—Prednisone—chronic obstructive pulmonary disease	6.13e-05	0.000448	CcSEcCtD
Oxaprozin—PTGS1—Selenium Micronutrient Network—TNF—chronic obstructive pulmonary disease	6.02e-05	0.00262	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism—APIP—chronic obstructive pulmonary disease	5.6e-05	0.00244	CbGpPWpGaD
Oxaprozin—PTGS2—Spinal Cord Injury—CXCL8—chronic obstructive pulmonary disease	5.43e-05	0.00236	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	5.37e-05	0.00234	CbGpPWpGaD
Oxaprozin—CYP2C9—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	5.29e-05	0.0023	CbGpPWpGaD
Oxaprozin—CYP2C9—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	5.22e-05	0.00227	CbGpPWpGaD
Oxaprozin—PTGS2—Spinal Cord Injury—IL1B—chronic obstructive pulmonary disease	5.21e-05	0.00227	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	5.03e-05	0.00219	CbGpPWpGaD
Oxaprozin—PTGS2—Spinal Cord Injury—MMP9—chronic obstructive pulmonary disease	4.91e-05	0.00214	CbGpPWpGaD
Oxaprozin—CYP2C9—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	4.86e-05	0.00212	CbGpPWpGaD
Oxaprozin—PTGS1—Selenium Micronutrient Network—IL6—chronic obstructive pulmonary disease	4.86e-05	0.00211	CbGpPWpGaD
Oxaprozin—CYP2C9—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	4.8e-05	0.00209	CbGpPWpGaD
Oxaprozin—PTGS2—Selenium Micronutrient Network—TNF—chronic obstructive pulmonary disease	4.78e-05	0.00208	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	4.67e-05	0.00203	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	4.63e-05	0.00202	CbGpPWpGaD
Oxaprozin—CYP2C9—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	4.61e-05	0.00201	CbGpPWpGaD
Oxaprozin—CYP2C9—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	4.55e-05	0.00198	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism—GC—chronic obstructive pulmonary disease	4.55e-05	0.00198	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	4.23e-05	0.00184	CbGpPWpGaD
Oxaprozin—PTGS2—Spinal Cord Injury—TGFB1—chronic obstructive pulmonary disease	4.05e-05	0.00176	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	3.99e-05	0.00174	CbGpPWpGaD
Oxaprozin—PTGS2—Spinal Cord Injury—EGFR—chronic obstructive pulmonary disease	3.97e-05	0.00173	CbGpPWpGaD
Oxaprozin—PTGS2—Selenium Micronutrient Network—IL6—chronic obstructive pulmonary disease	3.86e-05	0.00168	CbGpPWpGaD
Oxaprozin—PTGS2—Spinal Cord Injury—TNF—chronic obstructive pulmonary disease	3.78e-05	0.00164	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	3.71e-05	0.00162	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism—APIP—chronic obstructive pulmonary disease	3.71e-05	0.00161	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	3.68e-05	0.0016	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism—GC—chronic obstructive pulmonary disease	3.61e-05	0.00157	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	3.37e-05	0.00147	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	3.35e-05	0.00146	CbGpPWpGaD
Oxaprozin—PTGS2—Spinal Cord Injury—TP53—chronic obstructive pulmonary disease	3.33e-05	0.00145	CbGpPWpGaD
Oxaprozin—PTGS2—Spinal Cord Injury—IL6—chronic obstructive pulmonary disease	3.05e-05	0.00133	CbGpPWpGaD
Oxaprozin—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—chronic obstructive pulmonary disease	3e-05	0.00131	CbGpPWpGaD
Oxaprozin—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—chronic obstructive pulmonary disease	2.75e-05	0.0012	CbGpPWpGaD
Oxaprozin—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—chronic obstructive pulmonary disease	2.7e-05	0.00117	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	2.67e-05	0.00116	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	2.64e-05	0.00115	CbGpPWpGaD
Oxaprozin—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—chronic obstructive pulmonary disease	2.57e-05	0.00112	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism—GSTT1—chronic obstructive pulmonary disease	2.48e-05	0.00108	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	2.46e-05	0.00107	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism—GCLC—chronic obstructive pulmonary disease	2.45e-05	0.00107	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	2.44e-05	0.00106	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism—GC—chronic obstructive pulmonary disease	2.39e-05	0.00104	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	2.29e-05	0.000997	CbGpPWpGaD
Oxaprozin—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—chronic obstructive pulmonary disease	2.27e-05	0.000986	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism—CTGF—chronic obstructive pulmonary disease	2.24e-05	0.000975	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	2.22e-05	0.000967	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism—CYP1A2—chronic obstructive pulmonary disease	2.06e-05	0.000899	CbGpPWpGaD
Oxaprozin—PTGS2—Disease—HDAC2—chronic obstructive pulmonary disease	1.98e-05	0.000861	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.97e-05	0.000858	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism—GCLC—chronic obstructive pulmonary disease	1.95e-05	0.000848	CbGpPWpGaD
Oxaprozin—PTGS2—Disease—KL—chronic obstructive pulmonary disease	1.84e-05	0.000801	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	1.82e-05	0.000791	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism—CTGF—chronic obstructive pulmonary disease	1.78e-05	0.000774	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	1.77e-05	0.000771	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.72e-05	0.000749	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.7e-05	0.000739	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.64e-05	0.000713	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.58e-05	0.000689	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.5e-05	0.000653	CbGpPWpGaD
Oxaprozin—PTGS2—Disease—ERBB3—chronic obstructive pulmonary disease	1.38e-05	0.0006	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.37e-05	0.000595	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.35e-05	0.000587	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.31e-05	0.000568	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism—GCLC—chronic obstructive pulmonary disease	1.29e-05	0.000562	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.26e-05	0.000547	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	1.2e-05	0.000524	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.19e-05	0.000518	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism—CTGF—chronic obstructive pulmonary disease	1.18e-05	0.000513	CbGpPWpGaD
Oxaprozin—PTGS2—Disease—NOS2—chronic obstructive pulmonary disease	1.15e-05	0.000501	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.08e-05	0.000472	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism—ALB—chronic obstructive pulmonary disease	1.02e-05	0.000444	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism—NOS3—chronic obstructive pulmonary disease	9.75e-06	0.000425	CbGpPWpGaD
Oxaprozin—PTGS2—Disease—SERPINE1—chronic obstructive pulmonary disease	9.68e-06	0.000421	CbGpPWpGaD
Oxaprozin—PTGS2—Disease—NOS3—chronic obstructive pulmonary disease	9.24e-06	0.000402	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism—GSTP1—chronic obstructive pulmonary disease	9.05e-06	0.000394	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism—HMOX1—chronic obstructive pulmonary disease	8.92e-06	0.000389	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism—GSTM1—chronic obstructive pulmonary disease	8.32e-06	0.000362	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism—ALB—chronic obstructive pulmonary disease	8.09e-06	0.000352	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism—CYP1A1—chronic obstructive pulmonary disease	7.88e-06	0.000343	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism—NOS3—chronic obstructive pulmonary disease	7.74e-06	0.000337	CbGpPWpGaD
Oxaprozin—PTGS2—Disease—TGFB1—chronic obstructive pulmonary disease	6.11e-06	0.000266	CbGpPWpGaD
Oxaprozin—PTGS2—Disease—EGFR—chronic obstructive pulmonary disease	5.99e-06	0.000261	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism—ALB—chronic obstructive pulmonary disease	5.36e-06	0.000233	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism—NOS3—chronic obstructive pulmonary disease	5.13e-06	0.000223	CbGpPWpGaD
Oxaprozin—PTGS2—Disease—IL6—chronic obstructive pulmonary disease	4.61e-06	0.000201	CbGpPWpGaD
